Trial Profile
Open Label Trial of Hepcortespenlisimut-L (V5) Immunotherapy for HCC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Hepcortespenlisimut-L (Primary)
- Indications Liver cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Immunitor
- 27 Apr 2017 Results (n = 75) published in the Key Capital Group Media Release
- 13 Apr 2017 Results from this trial have been published in the Journal of Hepatocellular Carcinoma, according to a Key Capital Corporation media release.
- 13 Apr 2017 Results (n = 75) published in a Key Capital Corporation media release.